| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA030104 |
| P953 | full work available at URL | http://www.nejm.org/doi/pdf/10.1056/NEJMoa030104 |
| P698 | PubMed publication ID | 14585939 |
| P50 | author | Sam Schulman | Q40806287 |
| Henry Eriksson | Q76737365 | ||
| P2093 | author name string | Karin Wåhlander | |
| Torbjörn Lundström | |||
| Solveig Billing Clason | |||
| THRIVE III Investigators | |||
| P2860 | cites work | The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects | Q32067243 |
| A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. | Q33967251 | ||
| A prospective study of the incidence of deep-vein thrombosis within a defined urban population | Q33977258 | ||
| Antithrombotic therapy for venous thromboembolic disease | Q34131105 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators | Q43681404 | ||
| Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study | Q43750037 | ||
| Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial | Q44178713 | ||
| Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial | Q44217663 | ||
| Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans | Q44313272 | ||
| Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study | Q44437781 | ||
| Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects | Q44438922 | ||
| Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism | Q44548746 | ||
| A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis | Q47334930 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism. | Q52882861 | ||
| The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. | Q53361537 | ||
| Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis | Q73919544 | ||
| Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat | Q77747914 | ||
| Cost-effectiveness analyses | Q95780120 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | venous thromboembolism | Q9397786 |
| P304 | page(s) | 1713-1721 | |
| P577 | publication date | 2003-10-01 | |
| 2003-10-30 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran | |
| P478 | volume | 349 |
| Q64107484 | A Case Demonstrating the Ribaroxaban Therapy for Paradoxical Embolism |
| Q35852289 | A new oral anticoagulant: the 50-year challenge |
| Q36229356 | A preliminary assessment of the critical differences between novel oral anticoagulants currently in development |
| Q35747098 | A review of the clinical uses of ximelagatran in thrombosis syndromes |
| Q38151264 | Advantages and limitations of the new anticoagulants |
| Q37087993 | Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials |
| Q24807132 | Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran |
| Q57689199 | Anticoagulation for people with cancer and central venous catheters |
| Q57689042 | Anticoagulation for perioperative thromboprophylaxis in people with cancer |
| Q49834315 | Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. |
| Q24243286 | Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer |
| Q24194904 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer |
| Q24236620 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer |
| Q57689134 | Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer |
| Q33372751 | Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature. |
| Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q35878355 | Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management |
| Q48560063 | Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture |
| Q38388643 | Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. |
| Q35860195 | Challenges in the prevention of venous thromboembolism in the elderly |
| Q36474763 | Changing paradigms in the management of venous thromboembolism |
| Q46188988 | Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism |
| Q35977658 | Clinical experience with ximelagatran in orthopaedic surgery |
| Q35977667 | Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism |
| Q46906665 | Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran |
| Q47328874 | Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study |
| Q33365707 | Current issues in anticoagulation |
| Q37579455 | Dabigatran etexilate: future directions in anticoagulant treatment. |
| Q38241091 | Dabigatran excess: case report and review of the literature |
| Q81584045 | Deep vein thrombosis |
| Q45847579 | Diagnosis and anticoagulant treatment |
| Q56003308 | Direct Thrombin Inhibitors |
| Q24187415 | Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair |
| Q24200617 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
| Q94337721 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
| Q24244149 | Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparin for prevention of venous thromboembolism following total hip or knee replacement or hip repair |
| Q24235993 | Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement |
| Q28176666 | Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation |
| Q34284224 | Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term |
| Q36550717 | Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. |
| Q27027477 | Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis |
| Q38133389 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis |
| Q37428883 | Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. |
| Q36066023 | Emerging strategies for treatment of venous thromboembolism |
| Q28069617 | Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man |
| Q28081717 | Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis |
| Q64096953 | Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis |
| Q37844472 | Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated |
| Q36019805 | Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism |
| Q83067930 | Factor Xa and thrombin as targets for new oral anticoagulants |
| Q33590496 | Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) study |
| Q40519867 | Guidelines for the diagnosis, treatment, and follow-up of pulmonary embolism |
| Q36077273 | Hepatic findings in long-term clinical trials of ximelagatran |
| Q46896359 | Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran |
| Q39889806 | Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). |
| Q36764001 | Investigational treatments of venous thromboembolism |
| Q85246815 | Isolated Calf Vein Thrombosis Should Be Treated With Anticoagulation |
| Q93646291 | JournalScan |
| Q33375535 | Latest medical treatment strategies for venous thromboembolism |
| Q92152596 | Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis |
| Q37806826 | Long-term Anticoagulation for Venous Thromboembolism: Duration of Treatment and Management of Warfarin Therapy |
| Q33380411 | Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review |
| Q26828750 | Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis |
| Q36718482 | Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach |
| Q36590609 | Management of venous thromboembolism in the elderly |
| Q57254147 | Managing medical complications in patients with brain tumors |
| Q79680819 | Menorrhagia and minor bleeding symptoms in women on oral anticoagulation |
| Q89628720 | Milestone 9: Ximelagatran sets the stage for NOACs |
| Q98181527 | Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis |
| Q28081366 | New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs) |
| Q37806825 | New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors |
| Q37899258 | New anticoagulants - promising and failed developments. |
| Q24681351 | New anticoagulants for the prevention and treatment of venous thromboembolism |
| Q33370261 | New anticoagulants: anti IIa vs anti Xa--is one better? |
| Q36042279 | New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin |
| Q35860943 | New approaches to anticoagulation in atrial fibrillation |
| Q46832922 | New strategies in the secondary prevention of relapsing venous thromboembolism |
| Q45306740 | No effect of encapsulation on the pharmacokinetics of warfarin |
| Q51751921 | No influence of food on the pharmacokinetics, pharmacodynamics or tolerability of the 24mg and 36mg oral tablet formulations of ximelagatran. |
| Q45001577 | No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran |
| Q45001580 | No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. |
| Q37697501 | Novel oral anticoagulants to prevent stroke in atrial fibrillation |
| Q35779232 | Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin |
| Q34781477 | Optimal duration of anticoagulation after venous thromboembolism |
| Q47235947 | Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. |
| Q24186935 | Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis |
| Q24187205 | Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism |
| Q47551857 | Parenteral anticoagulation in ambulatory patients with cancer. |
| Q80044845 | Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers |
| Q55043926 | Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. |
| Q53150344 | Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation. |
| Q33419567 | Pharmacotherapy with oral Xa inhibitors for venous thromboembolism |
| Q37076516 | Predicting the future: it's not a SNP. |
| Q45241751 | Prevention of embolism among patients with atrial fibrillation |
| Q33359976 | Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors |
| Q79954098 | Pulmonary embolism |
| Q37903926 | Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. |
| Q34153343 | Risk assessment for recurrent venous thrombosis |
| Q46972220 | Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism |
| Q37578092 | Rivaroxaban in orthopedic surgery--a change of paradigm? |
| Q38827190 | Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis |
| Q36933765 | Should anticoagulation be resumed after intracerebral hemorrhage? |
| Q46921671 | Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies |
| Q35904418 | Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile |
| Q36925998 | Targeted inhibition of coagulation: oral agents show promise in phase III trials |
| Q44132363 | Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients |
| Q36905848 | The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. |
| Q38015427 | The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review |
| Q80098649 | The genetics of vitamin K antagonists |
| Q45006391 | The new anticoagulants are here! |
| Q44820370 | The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol |
| Q35996023 | The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism |
| Q33369274 | The role of ximelagatran in the treatment of venous thromboembolism |
| Q36520745 | The status of new anticoagulants |
| Q38086147 | Top practice-changing articles over the last two years |
| Q40458080 | Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. |
| Q44636983 | Treating Thrombosis in the 21st Century |
| Q48846277 | Treatment of Medical Complications in Patients with Brain Tumors |
| Q35977663 | Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran |
| Q36286443 | Update on the diagnosis and management of pulmonary embolism. |
| Q33945088 | Ximelagatran (Exanta): alternative to warfarin? |
| Q36216784 | Ximelagatran for stroke prevention in atrial fibrillation |
| Q36884659 | Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. |
| Q36745430 | Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials. |
| Q35843864 | Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations |
| Q46688989 | Ximelagatran--recent comparisons with warfarin |
| Q44960484 | Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs |
| Q33226419 | Ximelagatran: a new type of oral anticoagulant |
| Q35895188 | Ximelagatran: an oral direct thrombin inhibitor |
| Q24681333 | Ximelagatran: direct thrombin inhibitor |
| Q46686851 | Ximelagatran: hopes and controversies |
| Q35843153 | Ximelagatran: light at the end of the tunnel or the next tunnel? |
| Q35996015 | Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics |
| Q85334982 | [Dabigatran: transforming the management of oral anticoagulation] |
| Q80088631 | [New antitoagulants] |
| Q80984232 | [Therapeutical perspectives in systemic lupus erythematosus] |
| Q80938075 | [Treatment of deep vein thrombosis. When to use which substance?] |
| Q84564050 | [Treatment of postoperative thrombosis] |
| Q81512866 | [Treatment of venous thromboembolic disease] |
| Q81873866 | [Venous thromboembolism] |
Search more.